Ocular, Regeneron to develop sustained-release Eylea

Ocular Therapeutix Inc. (NASDAQ:OCUL) and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) will jointly develop a sustained-release formulation of Regeneron's ophthalmic drug Eylea aflibercept using Ocular's hydrogel-based technology. The partners said the formulation is in preclinical development.

Regeneron has an exclusive option to obtain worldwide rights to the formulation, as well as other biologics targeting VEGF for ophthalmic indications. If Regeneron exercises the option, Ocular would receive $10 million and would be responsible for development of the Eylea formulation through Phase I. ...